- Home
- TPG vs PCVX Comparison
TPG vs PCVX Comparison
Compare TPG & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TPG | PCVX |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 7.0B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TPG | PCVX |
|---|---|---|
| Price | $46.55 | $59.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 4 |
| Target Price | $61.20 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 2.4M | 1.1M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.89% | N/A |
| EPS Growth | ★ 207.14 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $4,670,212,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.79 | N/A |
| P/E Ratio | $273.29 | ★ N/A |
| Revenue Growth | ★ 33.43 | N/A |
| 52 Week Low | $36.95 | $31.89 |
| 52 Week High | $70.38 | $65.00 |
Technical Indicators
Market Signals| Indicator | TPG | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 38.71 | 49.63 |
| Support Level | $38.68 | $58.51 |
| Resistance Level | $55.20 | $63.39 |
| Average True Range (ATR) | 1.78 | 2.06 |
| MACD | -0.74 | -0.33 |
| Stochastic Oscillator | 13.89 | 39.58 |
Price Performance
Historical ComparisonAbout TPG TPG Inc.
TPG Inc is an alternative asset management firm. It invests across five multi-product platforms, namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company invests across a broadly diversified set of strategies, including private equity, impact, credit, real estate, market solutions, innovation, and inclusion.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.